January 23, 2019

Dr. Radulescu is a physician with 20 years of experience in the pharmaceutical industry. She brings to the RDT team strong strategic and operational medical leadership that will enhance the dialogue with pharmaceutical companies wanting to offer QuickStrip™ technology to their patient base. Dr. Radulescu has held a variety of posts within specialty pharmaceuticals across multiple therapeutic areas, including chronic inflammatory and cardio metabolic diseases, rare diseases as well as clinical operations and patient support programs. Dr. Radulescu has actively participated with commercialization teams at Astra Zeneca, Biogen, Takeda and Sobi across a broad range of pharmaceuticals including biologics and small market molecules entering the Canadian healthcare system.

“We are pleased to welcome Dr. Radulescu to the RDT family as Medical Director,“ said Mark Upsdell, CEO of RDT. “She brings a wealth of pharmaceutical experience across a diverse base of medical industry sectors — including health care, patient support, clinical trials, consumer products and infrastructure. Bringing Dr. Radulescu onto the RDT leadership team further demonstrates our commitment to develop therapeutic and pharmaceutical options based on our proprietary delivery technology QuickStrip™ with our continued focus on improving patients’ lives and health outcomes.”

"I believe RDT’s innovative drug delivery system will revolutionize how patients take low-dose health-care products. I am very excited about the opportunity to further develop RDT’s position within the healthcare and pharmaceutical landscape with QuickStrip™." added Dr. Radulescu.

Dr. Radulescu will be responsible for working in collaboration with our partners to develop a framework for evidence generation related to the benefits of enhanced delivery systems like QuickStrip™ in Canada, the US, and in South America in nutraceuticals, cannabis treatment options, and identified pharmaceutical therapeutic categories.

A Game-Changing Delivery System

About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian biotechnology company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. Through its wholly-owned subsidiary, Rapid Dose Therapeutics Inc., RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT’s QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT’s service based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs. For more information, visit: www.rapiddose.ca

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.